NewAmsterdam Pharma reports third quarter 2026 financial results
It receives European Commission approval for Ubeslo and Evlarco, starts SPINOZA Phase 2b, and posts $19.2 million revenue with $643.1 million cash.
See the latest news and media coverage for NewAmsterdam Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company developing cardiovascular and lipid-related treatments
newamsterdampharma.comLast updated
It receives European Commission approval for Ubeslo and Evlarco, starts SPINOZA Phase 2b, and posts $19.2 million revenue with $643.1 million cash.
Content covers LDL-C and Lp(a) reductions, exploratory MACE data, the ongoing PREVAIL CVOT, Alzheimer's biomarker results and about $643 million in cash.
The trial evaluates obicetrapib in about 400 adults with preclinical Alzheimer's disease, measuring change in plasma p-tau217 over 52 weeks.
The European Commission authorizes Ubeslo monotherapy and Evlarco fixed-dose combination for elevated LDL-C, marking obicetrapib's first global regulatory approval.
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has cleared a major regulatory hurdle. On September 21, it announced European Commission approval of Ubeslo, containing 10 mg of...
- First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability profile - - First global regulatory...
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies...
NAARDEN, the Netherlands and MIAMI, May 07, 2026 (GLOBE NEWSWIRE)-- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam” or the "Company”), a late-stage, clinical biopharmaceutical...
Track NewAmsterdam Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to NewAmsterdam Pharma and other trending companies.